艾曼妞3:爱的课程

China's pharmaceutical industry sees accelerated innovation breakthroughs in H1_我的网站

地球上最后一个人

一 | (ECNS) -- China's pharmaceutical industry accelerated innovation in the first half of this year, with domestic companies steadily improving their R&D capabilities and growth momentum continuing to strengthen, data showed. China's first broad-spectrum targeted anticancer drug entered clinical use at major hospitals across the country this year. It took only eight months to go from submission to market approval. A total of 38 innovative drugs were approved for marketing in China in the first half, of which 31 were developed domestically, more than 80% of the total. Eleven drugs featuring new targets or new mechanisms were all developed independently by domestic companies, producing a number of world-first innovations. By the end of 2025, China had 4,751 innovative drugs under development, one-third of the global total and the largest pipeline of any country. Behind this concentration of results lies a steadily strengthening industrial base. China has a complete pharmaceutical supply chain. It is not only the world's largest producer of active pharmaceutical ingredients but has also built a production system covering every pharmaceutical category. This year, digital, intelligent, and green technologies have driven the industry's transformation and upgrading. At a biopharmaceutical company in Shanxi Province, a newly built AI-powered bio-computing center can identify the structures of millions of protein functional domains in a short time, screening out ineffective molecules directly. To date, China has supported 21 pharmaceutical firms in building excellent-level smart factories and has cultivated more than 300 green factories. In the first half, the added value of pharmaceutical enterprises above the designated scale grew 6.4% year on year, and exports held strong. The world's first chemotherapy-sparing drug for gastric cancer, launched this year, had already earned overseas revenue through licensing deals before it reached the market, and is now exported to multiple countries and regions. In the first half, the total value of China's innovative drug out-licensing deals reached $110 billion, the industry's export delivery value grew 9% year on year, and high-value-added products made up nearly 20% of the total. (By Tang Yuxian) 。 8 月 26 日消息，针对网传上海特斯拉数据中心人去楼空的消息，特斯拉中国今天（26 日）向第一财经作出回应：“不实消息，已向公安机关报案。我们的数据中心正常运转，辅助驾驶招聘工作也在加速进行。相关工作都在稳步推进中。”而在今天早些时候，《每日经济新闻》则就同一网传内容向特斯拉中国方面求证，一位内部人士回应称“不实”。综合此前报道，特斯拉官网近期更新了 FSD 监督版全球可用地区清单。名单中包含了 12 个国家或地区，而中国不在此次公示的可用范围内。而在今年 5 月，特斯拉官方在 X 发文提到，监督版 FSD 支持的国家与地区中包含中国。公开信息显示，特斯拉目前仍在推进 FSD 监督版在中国市场的数据合规及本土化适配工作。